journal
MENU ▼
Read by QxMD icon Read
search

Journal of Hepatocellular Carcinoma

journal
https://read.qxmd.com/read/30666302/weighing-the-benefits-of-hepatocellular-carcinoma-surveillance-against-potential-harms
#1
REVIEW
Daniel Geh, Fahd A Rana, Helen L Reeves
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and usually occurs in people with liver cirrhosis. Both the incidence and mortality of HCC are increasing worldwide, making it a growing public health issue. HCC diagnosed at an early stage has a far better prognosis than HCC diagnosed at a late stage, mainly because early stage HCC can be treated with potentially curative therapies such as resection and transplantation. This makes surveillance for HCC in patients with liver cirrhosis an important strategy in improving outcomes...
2019: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/30643759/combined-hepatocellular-cholangiocarcinoma-chcc-cc-an-update-of-genetics-molecular-biology-and-therapeutic-interventions
#2
REVIEW
Chara Stavraka, Hannah Rush, Paul Ross
Combined hepatocellular cholangiocarcinoma (CC) is a rare and aggressive primary hepatic malignancy with significant histological and biological heterogeneity. It presents with more aggressive behavior and worse survival outcomes than either hepatocellular carcinoma or CC and remains a diagnostic challenge. An accurate diagnosis is crucial for its optimal management. Major hepatectomy with hilar node resection remains the mainstay of treatment in operable cases. Advances in the genetic and molecular characterization of this tumor will contribute to the better understanding of its pathogenesis and shape its future management...
2019: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/30613572/selecting-patients-with-hepatocellular-carcinoma-for-liver-transplantation-incorporating-tumor-biology-criteria
#3
REVIEW
Víctor Amado, Manuel Rodríguez-Perálvarez, Gustavo Ferrín, Manuel De la Mata
Liver transplantation (LT) is the optimal therapeutic option for patients with liver cirrhosis and hepatocellular carcinoma (HCC). Due to universal donor shortage, only the patients with limited tumor burden (under the so-called Milan criteria) are considered as potential candidates for LT in most institutions. It is expected that in the near future, more liver grafts will be available for patients with HCC due to the implementation of new direct antivirals against hepatitis C, leaving a prone scenario to consider expanding Milan criteria...
2019: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/30519546/hepatocellular-carcinoma-a-review-of-diagnostic-challenges-for-the-pathologist
#4
REVIEW
Alberto Quaglia
Histopathologists retain a critical role in the diagnosis and management of hepatocellular carcinoma (HCC). HCC arises usually but not exclusively in a background of advanced-stage chronic liver disease. The histological diagnosis of HCC poses many challenges particularly when dealing with liver biopsy specimens due to the heterogeneity of HCC and the difficulty to confirm hepatocellular differentiation in some instances. Primary liver tumors should be considered as a continuum with typical hepatocellular and cholangiocarcinoma at the two ends and a whole range of tumors showing both hepatocellular and cholangiocellular differentiation with or without an associated progenitor/stem cell component in the middle...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/30510922/sorafenib-plus-tegafur-uracil-uft-versus-sorafenib-as-first-line-systemic-treatment-for-patients-with-advanced-stage-hcc-a-phase-ii-trial-eslc01-study
#5
Hamdy A Azim, Ashraf Omar, Hesham Atef, Heba Zawahry, Mohamed K Shaker, Ah Kamel Abdelmaksoud, Mohamed EzzElarab, Omar Abdel-Rahman, Mohamed Ismail, Loay Kassem, Imam Waked
Background: Phase II trials found that tegafur-uracil (UFT) is an effective drug in hepatocellular carcinoma (HCC), while preclinical data suggested that its combination with sorafenib may have a promising activity. Our Phase II randomized trial aimed to evaluate efficacy and tolerability of sorafenib plus UFT vs sorafenib in advanced HCC. Methods: Patients with advanced HCC, with no prior systemic therapy, were randomized to receive either UFT at 125 mg/m2 twice daily for 4 out of 5 weeks plus sorafenib at 400 mg twice daily (arm 1) or single agent sorafenib at 400 mg twice daily (arm 2)...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/30464931/potential-of-ramucirumab-in-treating-hepatocellular-carcinoma-patients-with-elevated-baseline-alpha-fetoprotein
#6
REVIEW
Marine Gilabert, Jean-Luc Raoul
Hepatocellular carcinoma (HCC) represents ~90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improvement in overall survival over best supportive care in first- and second-line treatment. This study focused on the efficacy of antiangiogenics in patients with advanced HCC and particularly the rising role of ramucirumab in patients with elevated alpha-fetoprotein at diagnosis...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/30324097/update-on-hepatocellular-carcinoma-from-the-2018-gastrointestinal-cancer-symposium-asco-gi
#7
REVIEW
Victor Hugo Fonseca de Jesus, Aldo Lourenço Abbade Dettino
At the 2018 Gastrointestinal Cancer Symposium, sponsored by the American Society of Clinical Oncology, significant advances in the management of hepatocellular carcinoma (HCC) were announced. In intermediate-stage disease (Barcelona Clinic Liver Cancer stage B), interest in combining transarterial chemoembolization and sorafenib has been reignited as a consequence of the TACTICS trial. In advanced-stage disease (BCLC C), external-beam radiotherapy combined with transarterial chemoembolization proved to be superior to sorafenib in patients with portal vein thrombosis according to the START trial...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/30123783/hepatitis-c-virus-associated-hepatocellular-carcinoma-as-a-second-primary-malignancy-exposing-an-overlooked-presentation-of-liver-cancer
#8
Dima Dandachi, Manal Hassan, Ahmed Kaseb, Georgios Angelidakis, Harrys A Torres
Introduction: Chronic hepatitis C virus (HCV) infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Antiviral therapy in patients with HCV infection reduces the risk of primary HCC development by 71%-75%. HCV-infected patients with different primary cancers are also at risk for HCC development as a second primary malignancy (HCC-SPM). Limited information is available on the occurrence and characteristics of HCC-SPM. Herein, we determine the prevalence and clinical features of HCV-associated HCC-SPM when compared to primary HCC...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/30050880/hepatocellular-cancer-pain-impact-and-management-challenges
#9
REVIEW
Nathaniel Christian-Miller, Catherine Frenette
Hepatocellular carcinoma (HCC) remains the most common primary liver malignancy. Pain comprises one of the most pervasive and troubling symptoms of HCC and may have severely negative effects on patient's quality of life. Furthermore, because HCC frequently arises in the setting of cirrhosis, treating pain related to this malignancy poses a clinical challenge. This article summarizes manifestations of hepatocellular cancer pain, common obstacles to treatment, and practical HCC pain management.
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29984212/role-of-wnt-%C3%AE-catenin-signaling-in-hepatocellular-carcinoma-pathogenesis-and-clinical-significance
#10
REVIEW
Ahmed M Khalaf, David Fuentes, Ali I Morshid, Mata R Burke, Ahmed O Kaseb, Manal Hassan, John D Hazle, Khaled M Elsayes
Hepatocellular carcinoma (HCC) is one of the most common primary hepatic malignancies and one of the fastest-growing causes of cancer-related mortality in the United States. The molecular basis of HCC carcinogenesis has not been clearly identified. Among the molecular signaling pathways implicated in the pathogenesis of HCC, the Wnt/β-catenin signaling pathway is one of the most frequently activated. A great effort is under way to clearly understand the role of this pathway in the pathogenesis of HCC and its role in the transition from chronic liver diseases, including viral hepatitis, to hepatocellular adenomas (HCAs) and HCCs and its targetability in novel therapies...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29911076/decreased-hepatocellular-carcinoma-tumor-burden-with-the-achievement-of-hepatitis-c-virus-sustained-virologic-response-unlocking-the-potential-of-t-cell-mediated-immunosurveillance
#11
Anna S Griffith, Paul H Hayashi, Lauren Mb Burke, Autumn J McRee
We describe two cases of patients with hepatitis C virus (HCV) treated with direct-acting antiviral (DAA) therapy who had dramatic improvement in hepatocellular carcinoma (HCC) tumor burden with DAA therapy alone. Both patients were diagnosed with HCC on screening magnetic resonance imaging shortly after beginning DAA therapy. Both patients achieved sustained virologic response (SVR) with dramatic improvement in HCC tumor burden on follow-up imaging without HCC treatment. Patients with multifocal or advanced HCC are infrequently treated with antiviral therapy for HCV...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29774205/editorial-charting-the-future-of-hepatocellular-carcinoma-publications
#12
EDITORIAL
Ahmed Omar Kaseb
No abstract text is available yet for this article.
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29520343/efficacy-of-loco-regional-treatment-for-hepatocellular-carcinoma-prior-to-living-donor-liver-transplantation-a-report-from-a-single-center-in-egypt
#13
Mohammad Kamal Shaker, Iman F Montasser, Mohamed Sakr, Mohamed Elgharib, Hany M Dabbous, Hend Ebada, Ahmed El Dorry, Mohamed Bahaa, Mahmoud El Meteini
Background and aim: The number of loco-regional therapies (LRTs) for hepatocellular carcinoma (HCC) has increased dramatically during the past decade, bridging or downstaging patients on the waiting list for liver transplantation. This study aimed to analyze the outcomes of LRTs prior to living donor liver transplantation in patients with HCC. Methods: Sixty-two HCC patients received living donor liver transplantation at Ain Shams Center for Organ Transplantation over a 2-year period...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29404284/pretreatment-neutrophil-lymphocyte-ratio-useful-prognostic-biomarker-in-hepatocellular-carcinoma
#14
REVIEW
Marc Najjar, Surbhi Agrawal, Jean C Emond, Karim J Halazun
Hepatocellular carcinoma (HCC) is the most common liver malignancy and the third most common cause of cancer-related deaths. Liver resection (LR) and liver transplantation (LT) are the only curative modalities for HCC. Despite recent advances and the adoption of the Milan and University of California, San Francisco, criteria, HCC recurrence after LR and LT remains a challenge. Several markers and prognostic scores have been proposed to predict tumor aggressiveness and supplement radiological data; among them, neutrophil-lymphocyte ratio (NLR) has recently gained significant interest...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29392123/phase-ii-trial-of-som230-pasireotide-lar-in-patients-with-unresectable-hepatocellular-carcinoma
#15
Lynn G Feun, Medhi Wangpaichitr, Ying-Ying Li, Deukwoo Kwon, Stephen P Richman, Peter J Hosein, Niramol Savaraj
Background: A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic hepatocellular carcinoma (HCC). Patients and methods: Patients with advanced HCC and Child-Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days. Primary endpoint was disease control rate. Secondary endpoints were time to tumor progression, response rate, treatment-related adverse events, and overall survival. Serum insulin growth factor-1 was measured before and after pasireotide...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29392122/liver-resection-versus-radiofrequency-ablation-for-hepatitis-b-virus-related-small-hepatocellular-carcinoma
#16
Bin Liang, Siyang Yao, Jiapeng Zhou, Zongkui Li, Tianqi Liu
Background: To compare the outcomes of liver resection (LR) with radiofrequency ablation (RFA) for patients with hepatitis B virus (HBV)-related small hepatocellular carcinoma (HCC). Methods: A total of 122 HBV-related small HCC patients who underwent LR (n=64) or RFA (n=58) were involved in this retrospective study. Their basic clinical data, postoperative complications, survival outcomes, and prognostic factors were compared and analyzed. Results: Patients in the LR group had more serious complications (11 versus 0) and longer postoperative hospital stays (11...
2018: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29692983/basic-mri-for-the-liver-oncologists-and-surgeons
#17
REVIEW
Lan N Vu, John N Morelli, Janio Szklaruk
Magnetic resonance imaging (MRI) is the modality of choice for liver imaging due to its superior contrast resolution in comparison with computer tomography and the ability to provide both morphologic and physiologic information. The physics of MR are complex, and a detailed understanding is not required to appreciate findings on an MRI exam. Here, we attempt to introduce the basic principles of MRI with respect to hepatic imaging focusing on various commonly encountered hepatic diseases. The purpose is to facilitate an appreciation of the various diagnostic capabilities of MR among hepatic oncologists and surgeons and to foster an understanding of when MR studies may be appropriate in the care of their patients...
2017: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29238703/characterization-of-alpha-fetoprotein-effects-on-dendritic-cell-and-its-function-as-effector-immune-response-activator
#18
Jeremiah Suryatenggara, Heri Wibowo, Wahyuni Lukita Atmodjo, George Mathew
Tumor antigen alpha-fetoprotein (AFP) can promote immune tolerance toward tumor cells by inducing regulatory functions of the immune system. The purpose of this study was to characterize the effects of AFP on dendritic cells (DC) in their antitumor immune response stimulation and subsequent immune tolerance toward tumor cells. Monocytes were cultured in medium with GM-CSF and IL-4 and incubated for 6 days to generate immature DC (imDC). AFP was added into the treatment group at the beginning of the monocyte-derived DC culture...
2017: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29184856/optimal-therapy-for-patients-with-hepatocellular-carcinoma-and-resistance-or-intolerance-to-sorafenib-challenges-and-solutions
#19
REVIEW
Emily M Ray, Hanna K Sanoff
The only US Food and Drug Administration (FDA)-approved first-line systemic therapy for hepatocellular carcinoma (HCC) is sorafenib; however, resistance or intolerance to sorafenib is unfortunately common. In this review, we briefly describe systemic therapies that can be considered for patients with HCC who show resistance or intolerance to sorafenib. For all patients with HCC who need systemic therapy, we strongly advocate for participation in clinical trials. Cytotoxic chemotherapy plays a minor role in the treatment of advanced HCC, with some data supporting the use of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) and GEMOX (gemcitabine-oxaliplatin)...
2017: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/29082223/healthcare-costs-of-transarterial-chemoembolization-in-the-treatment-of-hepatocellular-carcinoma
#20
Waleed Fateen, Farooq Khan, Richard J O'Neill, Martin W James, Stephen D Ryder, Guruprasad P Aithal
BACKGROUND: A meta-analysis comparing drug-eluting beads transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (cTACE) has recently been published. On balance, no significant differences were found in terms of objective response and overall survival. The impact on healthcare costs had been studied in small series based on a hypothetical model and was in favor of DEB-TACE. We aimed to evaluate and compare health-care costs and effectiveness of both modalities in a cohort of patients from Nottingham, UK...
2017: Journal of Hepatocellular Carcinoma
journal
journal
53528
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"